WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206118

CAS#: 1044870-39-4

Description: Apabetalone, also known as RVX-208, is a potent inhibitor of BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT). RVX-208 increases the production of ApoA-I in hepatocytes in vitro, and in vivo in monkeys and humans, which results in increased HDL-C, but the molecular target was not previously reported. RVX-208 may be a promising new approach to the treatment of atherosclerosis.

Chemical Structure

CAS# 1044870-39-4

Theoretical Analysis

MedKoo Cat#: 206118
Name: Apabetalone
CAS#: 1044870-39-4
Chemical Formula: C20H22N2O5
Exact Mass: 370.15287
Molecular Weight: 370.39908
Elemental Analysis: C, 64.85; H, 5.99; N, 7.56; O, 21.60

Price and Availability

Size Price Availability Quantity
50.0mg USD 150.0 Same Day
100.0mg USD 250.0 Same Day
200.0mg USD 450.0 Same Day
500.0mg USD 950.0 Same Day
1.0g USD 1450.0 Same Day
2.0g USD 2450.0 Same Day
5.0g USD 4250.0 Same Day
10.0g USD 6950.0 Same Day
Click to view more sizes and prices
Bulk inquiry

Synonym: RVX208; RVX 208; RVX-208; Apabetalone.

IUPAC/Chemical Name: 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one


InChi Code: InChI=1S/C20H22N2O5/c1-11-7-13(8-12(2)18(11)27-6-5-23)19-21-15-9-14(25-3)10-16(26-4)17(15)20(24)22-19/h7-10,23H,5-6H2,1-4H3,(H,21,22,24)


Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 370.39908 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Barylski M, Toth PP, Nikolic D, Banach M, Rizzo M, Montalto G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):453-61. doi: 10.1016/j.beem.2013.11.001. Epub 2013 Nov 15. PubMed PMID: 24840270.

2: McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E, Suto RK, Wong NC, Wagner GS, Hansen HC, Young PR. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013 Dec 31;8(12):e83190. doi: 10.1371/journal.pone.0083190. eCollection 2013. PubMed PMID: 24391744; PubMed Central PMCID: PMC3877016.

3: Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Müller S, Brennan PE, Knapp S, Filippakopoulos P. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9. doi: 10.1073/pnas.1310658110. Epub 2013 Nov 18. PubMed PMID: 24248379; PubMed Central PMCID: PMC3856850.

4: Balder JW, Staels B, Kuivenhoven JA. Pharmacological interventions in human HDL metabolism. Curr Opin Lipidol. 2013 Dec;24(6):500-9. doi: 10.1097/MOL.0000000000000018. Review. PubMed PMID: 24184942.

5: Khmelnitsky YL, Mozhaev VV, Cotterill IC, Michels PC, Boudjabi S, Khlebnikov V, Madhava Reddy M, Wagner GS, Hansen HC. In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208). Eur J Med Chem. 2013 Jun;64:121-8. doi: 10.1016/j.ejmech.2013.03.062. Epub 2013 Apr 10. PubMed PMID: 23644195.

6: Joy TR. Novel HDL-based therapeutic agents. Pharmacol Ther. 2012 Jul;135(1):18-30. doi: 10.1016/j.pharmthera.2012.03.004. Epub 2012 Mar 23. Review. PubMed PMID: 22465158.

7: Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Wong NC, Borgman MR, Nissen SE. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012 Apr;26(2):181-7. doi: 10.1007/s10557-012-6373-5. PubMed PMID: 22349989.

8: Rvx 208. Drugs R D. 2011;11(2):207-13. doi: 10.2165/11595140-000000000-00000. Review. PubMed PMID: 21679009; PubMed Central PMCID: PMC3585949.

9: Shah PK. Atherosclerosis: targeting endogenous apo A-I--a new approach for raising HDL. Nat Rev Cardiol. 2011 Apr;8(4):187-8. doi: 10.1038/nrcardio.2011.37. Epub 2011 Mar 1. PubMed PMID: 21364534.

10: Horowitz JD, Rosenson RS, McMurray JJ, Marx N, Remme WJ. Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther. 2011 Feb;25(1):69-76. doi: 10.1007/s10557-011-6285-9. PubMed PMID: 21340529.

11: Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJ, Taylor A, Borgman M, Nissen SE. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011 Mar 1;57(9):1111-9. doi: 10.1016/j.jacc.2010.11.015. Epub 2011 Jan 20. PubMed PMID: 21255957.

12: Davidson MH. Apolipoprotein A-I therapy promise, challenges, and disappointment. J Am Coll Cardiol. 2011 Mar 1;57(9):1120-1. doi: 10.1016/j.jacc.2010.11.025. Epub 2011 Jan 20. PubMed PMID: 21255956.

13: Inazu A. [Novel therapy for atherosclerosis and inflammatory vascular disease]. Nihon Rinsho. 2011 Jan;69(1):105-9. Review. Japanese. PubMed PMID: 21226269.

14: Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, Genest J. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010 Jun 8;55(23):2580-9. doi: 10.1016/j.jacc.2010.02.035. Erratum in: J Am Coll Cardiol. 2010 Aug 31;56(10):825. PubMed PMID: 20513599.

15: McNeill E. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Curr Opin Investig Drugs. 2010 Mar;11(3):357-64. Review. PubMed PMID: 20178050.

16: Wong NC. Coronary Artery Disease - Eighth International Congress. From prevention to intervention. IDrugs. 2009 Dec;12(12):742-6. PubMed PMID: 19943213.


Additional Information